{"id":391058,"date":"2016-09-19T00:00:00","date_gmt":"2016-09-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrid0004-2016-biopharma-hepatitis-c-virus-current-treatment-eu5-2016\/"},"modified":"2026-03-31T09:01:42","modified_gmt":"2026-03-31T09:01:42","slug":"cutrid0004-2016-biopharma-hepatitis-c-virus-current-treatment-eu5-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrid0004-2016-biopharma-hepatitis-c-virus-current-treatment-eu5-2016\/","title":{"rendered":"Hepatitis C Virus | Current Treatment | EU5 | 2016"},"content":{"rendered":"<p>Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma in the EU5 and a common indication for liver transplantation. The 2013-2015 EMA authorizations of Gilead\u2019s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir\/ledipasvir), combined with Bristol-Myers Squibb\u2019s Daklinza (daclatasvir) and AbbVie\u2019s Viekirax +\/- Exviera (ombitasvir\/paritaprevir\/ritonavir +\/- dasabuvir), have ushered in the era of IFN-free therapy for chronic HCV and completely reshaped the HCV therapeutic market. Recent EMA approvals of Gilead\u2019s Epclusa (sofosbuvir\/velpatasvir) and Merck Sharpe &#038; Dohme\u2019s Zepatier (elbasvir\/grazoprevir) provide additional IFN-free options for EU5 HCV patients. Taken together, currently approved regimens provide efficacious IFN-free options for most HCV genotypes in the EU5. This research focuses on current and anticipated use of all-oral HCV regimens, including IFN-free and remaining IFN-based regimens, by capturing patient- and market-share data, current prescribing trends, and anticipated changes in prescribing and treatment. We also evaluate physician-perceived drivers and limitations to the uptake of key brands and the effectiveness\u00a0of these agents\u2019\u00a0salesforces.<\/p>\n","protected":false},"template":"","class_list":["post-391058","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hepatitis-c-virus","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391058","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391058\/revisions"}],"predecessor-version":[{"id":576869,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391058\/revisions\/576869"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391058"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}